+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Recombinant Coagulation Factor Concentrate Market by Factor Viii (Extended Half Life, Standard Half Life), Factor Ixh (Extended Half Life, Standard Half Life), Factor Vii - Global Forecast 2025-2030- Product Image
Recombinant Coagulation Factor Concentrate Market by Factor Viii (Extended Half Life, Standard Half Life), Factor Ixh (Extended Half Life, Standard Half Life), Factor Vii - Global Forecast 2025-2030- Product Image
New

Recombinant Coagulation Factor Concentrate Market by Factor Viii (Extended Half Life, Standard Half Life), Factor Ixh (Extended Half Life, Standard Half Life), Factor Vii - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6143163
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The landscape of coagulation therapy is undergoing profound transformation as recombinant factor concentrates redefine treatment paradigms for individuals with hemophilia and related bleeding disorders. Historically, plasma-derived products presented challenges in supply consistency and pathogen safety. The advent of recombinant technology marked a turning point by ensuring consistent purity, reducing immunogenic risk, and enabling scalable manufacturing processes. With these advancements, healthcare providers have been empowered to offer individualized dosing regimens that enhance patient outcomes while minimizing adverse events.

Furthermore, the integration of novel molecular engineering techniques has led to the emergence of variants with optimized properties, such as extended half-lives that reduce infusion frequency and improve patient adherence. These scientific breakthroughs have been complemented by robust regulatory frameworks that prioritize safety, efficacy, and traceability. As the therapeutic toolkit for hemophilia expands, stakeholders are compelled to consider not only the clinical benefits but also the economic and operational implications of transitioning to recombinant alternatives. In this context, a comprehensive understanding of technological, regulatory, and clinical dimensions is essential for stakeholders seeking to navigate the evolving coagulation therapy ecosystem.

Emerging Protein Engineering Innovations and Digital Health Convergence Reshaping the Future of Recombinant Coagulation Therapy

In recent years, several paradigm shifts have accelerated progress in the recombinant coagulation factor concentrate arena. Cutting-edge protein engineering methodologies, such as site-specific pegylation and fusion to immunoglobulin fragments, have generated products with significantly prolonged circulation times. These innovations directly address longstanding adherence barriers by reducing infusion frequency, thereby facilitating more sustainable treatment regimens.

Equally transformative has been the shift toward patient-centric delivery models. The integration of digital health platforms and remote monitoring tools enables real-time tracking of dosing adherence, bleeding events, and patient-reported outcomes. This digital convergence fosters more personalized care pathways, allowing clinicians to tailor treatment plans based on dynamic patient data. Moreover, collaborations between biopharmaceutical firms and contract manufacturing organizations have optimized production efficiencies, ensuring that emerging therapies can be scaled rapidly in response to clinical demand.

Strategic Adaptations in Supply Chain Procurement and Reimbursement Models Following 2025 United States Tariff Adjustments

The introduction of revised tariff structures in the United States in 2025 has exerted considerable influence on the recombinant coagulation factor concentrate supply chain. Import duties on raw materials and certain bioprocessing reagents have prompted manufacturers to reassess procurement channels and negotiate with domestic suppliers where feasible. This shift toward nearshoring and strategic diversification of raw material sources has mitigated exposure to tariffs while ensuring continuity of manufacturing operations.

In parallel, pricing strategies have been recalibrated to reflect incremental input costs without undermining patient access. Some manufacturers have entered into value-based contracting arrangements with payers, aligning reimbursement with real-world clinical outcomes. This approach has not only maintained affordability for healthcare systems but also preserved innovation incentives. As a result, stakeholders are navigating a balance between cost pressures and the imperative to sustain investment in next-generation therapies.

Nuanced Differentiation of Factor VIII IX and VII Therapeutic Variants Highlighting Extended Versus Standard Half-Life Development Pathways

Insight into the recombinant coagulation factor concentrate market is enhanced by examining specific product segments. For Factor VIII, development has focused on both extended half-life variants and standard half-life formulations, with extended half-life constructs further differentiated by albumin fusion, Fc fusion, and pegylated technologies to optimize pharmacokinetics. A parallel segmentation framework applies to Factor IX, where extended half-life options leverage similar fusion strategies alongside conventional standard half-life molecules. Contrastingly, Factor VII products remain exclusively within the standard half-life category, reflecting established therapeutic protocols and clinical familiarity.

Understanding these segmentation nuances is critical for stakeholders aiming to align research pipelines with emerging clinical needs. Extended half-life constructs have demonstrated the potential to reduce infusion frequency and improve quality of life, whereas standard half-life variants continue to serve as reliable options in acute management scenarios. This segmentation perspective underscores the importance of tailored development strategies that address both incremental improvements and foundational therapeutic requirements.

Distinct Regional Dynamics Governing Adoption Reimbursement and Manufacturing Strategies Across Americas Europe Middle East Africa and Asia Pacific

A regional perspective reveals distinct dynamics across global markets for recombinant coagulation factor concentrates. In the Americas, established healthcare infrastructures and reimbursement frameworks have facilitated early adoption of next-generation therapies, with payers demonstrating willingness to support value-based agreements. This has encouraged manufacturers to introduce extended half-life products accompanied by robust pharmacoeconomic evidence.

In Europe, the Middle East, and Africa, regulatory harmonization efforts and pan-regional procurement initiatives have bolstered market access for innovative therapeutics, although pricing and reimbursement processes vary widely. Emerging economies within this region are increasingly prioritizing local manufacturing partnerships to strengthen supply security and reduce dependency on imports.

Within the Asia-Pacific region, expanding healthcare coverage and rising awareness of hemophilia management are driving demand for both standard and extended half-life recombinant products. Regional players are investing in biomanufacturing capabilities while forging strategic collaborations to expedite commercialization. Continued government support for biosimilar development further shapes competitive dynamics and cost considerations.

Strategic R D Investments Alliance Formations and Pipeline Optimization Driving Competitive Differentiation Among Leading Therapeutic Developers

Leading biopharmaceutical organizations have distinguished themselves through targeted investments in research and development, strategic partnerships, and portfolio optimization. Some have invested heavily in novel fusion and modification platforms to secure a competitive edge in extended half-life therapies, aligning their pipelines with emerging clinical expectations. Others have concentrated on clinical evidence generation, conducting head-to-head studies to substantiate real-world benefits and to support differentiated positioning with payers.

In addition, several companies have pursued manufacturing excellence by expanding capacity and streamlining supply chains. Collaborative alliances with contract development and manufacturing organizations have enabled scalable production while maintaining stringent quality controls. Furthermore, a cohort of specialized firms has focused on niche applications, such as immune tolerance induction and pediatric formulations, reinforcing the diversification of strategic approaches in the sector.

Tactical Roadmap for Developing Enhanced Therapeutics Strengthening Digital Integration and Forging Collaborative Ecosystems to Drive Sustainable Growth

Industry leaders should prioritize the integration of advanced molecular design techniques to develop next-generation coagulation factor variants with optimized pharmacokinetics and reduced immunogenicity. Complementing these efforts with real-world evidence programs will strengthen payer negotiations and support value-based contracting models. Shifting procurement strategies toward geographically diversified supply chains will mitigate tariff-related risks and enhance operational resilience.

Moreover, forging collaborations with digital health innovators can yield integrated platforms for patient monitoring and adherence support, deepening engagement and fostering outcome-driven care. Engaging early with regulatory authorities to align on clinical trial design and post-market evidence requirements will expedite approvals and market entry. Finally, exploring joint ventures with regional partners can accelerate access in emerging markets while sharing developmental and commercial responsibilities.

Robust Mixed Methods Research Framework Integrating Expert Perspectives Regulatory Data and Strategic Announcements for Comprehensive Analysis

This research initiative employed a mixed-methods approach, combining qualitative expert interviews with quantitative secondary data analysis sourced from regulatory filings, clinical trial registries, and publicly available corporate disclosures. Industry specialists were consulted across biopharmaceutical development, regulatory affairs, and health economics to validate key insights and contextualize emerging trends.

Data triangulation was performed by cross-referencing findings with patent databases, peer-reviewed literature, and strategic announcements from leading organizations. Regional dynamics were examined through country-level regulatory guidelines and procurement frameworks, ensuring that insights reflect localized considerations. Finally, methodological rigor was ensured through iterative validation sessions with internal analysts, reinforcing the accuracy and relevance of the findings.

Strategic Synthesis of Technological Regulatory and Economic Drivers Shaping the Future Landscape of Coagulation Factor Therapies

The recombinant coagulation factor concentrate arena is positioned at the nexus of technological innovation, regulatory evolution, and shifting healthcare economics. Extended half-life variants and digital health integration are redefining patient-centric care, while regional nuances demand adaptive market entry and supply chain strategies. Tariff-induced cost pressures have catalyzed supply chain realignment and novel reimbursement pathways, underscoring the need for agile operational frameworks.

As the sector continues to evolve, success will hinge on the ability of organizations to anticipate shifts in clinical practice, engage collaboratively across the ecosystem, and harness real-world evidence to substantiate value propositions. By aligning strategic investments with patient needs and payer expectations, stakeholders can navigate the complexity of the coagulation therapy market and drive sustainable innovation that ultimately improves patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Factor Viii
    • Extended Half Life
      • Albumin Fusion
      • Fc Fusion
      • Pegylated
    • Standard Half Life
  • Factor Ixh
    • Extended Half Life
      • Albumin Fusion
      • Fc Fusion
      • Pegylated
    • Standard Half Life
  • Factor Vii
    • Standard Half Life
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • CSL Behring GmbH
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Grifols, S.A.
  • Swedish Orphan Biovitrum AB (publ)
  • LFB S.A.
  • Shanghai RAAS Blood Products Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising market uptake of extended half-life recombinant factor concentrates to reduce infusion frequency
5.2. Growing competition from factor VIII biosimilars driving pricing pressure across mature markets
5.3. Implementation of patient support programs and digital adherence tools in hemophilia care pathways
5.4. Increasing investment in Asia Pacific infrastructure for local production of recombinant factors
5.5. Regulatory approvals of novel recombinant factor IX fusion proteins enhancing product differentiation
5.6. Shift toward value-based contracting models with payers to improve access to recombinant therapies
5.7. Emergence of point-of-care testing devices enabling personalized dosing of coagulation factors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Recombinant Coagulation Factor Concentrate Market, by Factor Viii
8.1. Introduction
8.2. Extended Half Life
8.2.1. Albumin Fusion
8.2.2. Fc Fusion
8.2.3. Pegylated
8.3. Standard Half Life
9. Recombinant Coagulation Factor Concentrate Market, by Factor Ixh
9.1. Introduction
9.2. Extended Half Life
9.2.1. Albumin Fusion
9.2.2. Fc Fusion
9.2.3. Pegylated
9.3. Standard Half Life
10. Recombinant Coagulation Factor Concentrate Market, by Factor Vii
10.1. Introduction
10.2. Standard Half Life
11. Americas Recombinant Coagulation Factor Concentrate Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Recombinant Coagulation Factor Concentrate Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Recombinant Coagulation Factor Concentrate Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. CSL Behring GmbH
14.3.2. Takeda Pharmaceutical Company Limited
14.3.3. Bayer AG
14.3.4. Pfizer Inc.
14.3.5. Novo Nordisk A/S
14.3.6. Octapharma AG
14.3.7. Grifols, S.A.
14.3.8. Swedish Orphan Biovitrum AB (publ)
14.3.9. LFB S.A.
14.3.10. Shanghai RAAS Blood Products Co., Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET: RESEARCHAI
FIGURE 22. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET: RESEARCHSTATISTICS
FIGURE 23. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET: RESEARCHCONTACTS
FIGURE 24. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY ALBUMIN FUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY ALBUMIN FUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FC FUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FC FUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY PEGYLATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY PEGYLATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY ALBUMIN FUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY ALBUMIN FUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FC FUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FC FUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY PEGYLATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY PEGYLATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 65. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 66. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 67. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 68. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 69. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 70. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 71. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 72. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 73. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 74. CANADA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 75. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 76. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 77. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 78. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 79. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 80. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 81. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 82. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 83. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 84. MEXICO RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 95. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 96. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 97. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 98. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 118. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 120. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 127. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 128. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 129. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 130. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 131. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 132. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 133. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 134. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 135. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 136. GERMANY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 137. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 138. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 139. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 140. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 141. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 142. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 143. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 144. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 145. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 146. FRANCE RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 147. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 148. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 149. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 150. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 157. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 158. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 159. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 160. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 161. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 162. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 163. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 164. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 165. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 166. ITALY RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 167. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 168. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 169. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 170. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 171. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 172. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 173. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 174. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 175. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 176. SPAIN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 188. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 190. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 198. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 200. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 207. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 208. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 209. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 210. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 211. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 212. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 213. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 214. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 215. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 216. DENMARK RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 217. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 218. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 219. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 220. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 227. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 228. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 229. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 230. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 231. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 232. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 233. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 234. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 235. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 236. QATAR RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 237. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 238. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 239. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 240. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 241. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 242. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 243. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 244. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 245. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 246. FINLAND RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 247. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 248. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 249. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 250. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 257. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 258. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 259. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 260. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2025-2030 (USD MILLION)
TABLE 267. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 268. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 269. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 270. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 271. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2018-2024 (USD MILLION)
TABLE 272. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR IXH, 2025-2030 (USD MILLION)
TABLE 273. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 274. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 275. EGYPT RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET SIZE, BY FACTOR VII, 2018-2024 (USD MILLION)
TABLE 276

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Recombinant Coagulation Factor Concentrate market report include:
  • CSL Behring GmbH
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Grifols, S.A.
  • Swedish Orphan Biovitrum AB (publ)
  • LFB S.A.
  • Shanghai RAAS Blood Products Co., Ltd.

Related Topics

Related Reports

Coagulation Factor Concentrates Market by Product Type (Plasma Derived, Recombinant), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease), Formulation, End User, Distribution Channel, Route Of Administration - Global Forecast 2025-2030 - Product Image

Coagulation Factor Concentrates Market by Product Type (Plasma Derived, Recombinant), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease), Formulation, End User, Distribution Channel, Route Of Administration - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Coagulation Factor Concentrates - Global Strategic Business Report - Product Image

Coagulation Factor Concentrates - Global Strategic Business Report

  • Report
  • 129 Pages
  • Global
From
Recombinant Coagulation Factors - Global Strategic Business Report - Product Image

Recombinant Coagulation Factors - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030 - Product Image

Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

  • Report
  • Global
From
Coagulation Factor Deficiency Global Market Report 2025 - Product Image

Coagulation Factor Deficiency Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.